90%Confidence
0Views
FDASource
2026-04-10Date
Summary
Another Class II recall for Teva's Octreotide Acetate (10 mg) reinforces systemic sterility problems at the same Greek contract manufacturer, signaling broader quality failures across multiple dosages. This could result in regulatory actions, inventory write-offs, and eroded trust in Teva's brand for specialty injectables.
Actionable: Consider reducing exposure to Teva until they demonstrate improved quality control over their contract manufacturing partners.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now